Haynes Boone advised Oncocyte Corp. (Nasdaq: OCX) on a successful $29.1 million registered direct offering and concurrent private placement.
The financing, led by Oncocyte’s five largest shareholders, is expected to fully fund the company’s FDA In-Vitro Diagnostic (IVD) transplant assay program through regulatory approval and commercialization.
The transaction included the sale of 3,609,755 shares of common stock in the registered direct offering and 7,536,708 shares of common stock, along with pre-funded warrants to buy 3,069,925 shares, in the private placement. Both offerings were priced at $2.05 per share, with no discounts or incentive warrants.
Haynes Boone Capital Markets Partners Greg Kramer and Alok Choksi led the deal team with support from Associates Cheyenne Karp, Perry Laub and Sean Tierney.
Haynes Boone's Capital Markets practice has played a leading role in numerous IPOs, follow-on offerings, SPAC transactions and PIPE financings in recent years across sectors including technology, life sciences, energy and financial services. The firm provides comprehensive advice to clients trading on all major U.S. securities exchanges, over-the-counter markets and many foreign markets on a full range of securities transactions and reporting matters.
The financing, led by Oncocyte’s five largest shareholders, is expected to fully fund the company’s FDA In-Vitro Diagnostic (IVD) transplant assay program through regulatory approval and commercialization.
The transaction included the sale of 3,609,755 shares of common stock in the registered direct offering and 7,536,708 shares of common stock, along with pre-funded warrants to buy 3,069,925 shares, in the private placement. Both offerings were priced at $2.05 per share, with no discounts or incentive warrants.
Haynes Boone Capital Markets Partners Greg Kramer and Alok Choksi led the deal team with support from Associates Cheyenne Karp, Perry Laub and Sean Tierney.
Haynes Boone's Capital Markets practice has played a leading role in numerous IPOs, follow-on offerings, SPAC transactions and PIPE financings in recent years across sectors including technology, life sciences, energy and financial services. The firm provides comprehensive advice to clients trading on all major U.S. securities exchanges, over-the-counter markets and many foreign markets on a full range of securities transactions and reporting matters.
